Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Irish Pharmaceutical Healthcare Association .
Filed returns
182
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | Budget 2025 (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | IPHA General Election Manifesto asks - (i) Faster Access to new Medicines and (ii) Increased number of Clinical Trials. (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | Issues concerning the timely reimbursement of medicines in Ireland. (Public policy or programme) | 13 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | EU Competitiveness and pharmaceutical industry - Draghi Report (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | European Commission Urban Waste Water Treatment Directive (UWWTD), with particular attention to the polluter payers principal and proportional responsibility. (Legislation) | 8 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | IPHA Programme for Government asks - (i) Support IP Rights for medicines in Europe; (ii) Faster access to new medicines and (iii) A Life Science Policy for Ireland (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | European competitiveness and pharmaceutical industry's role therein. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | IPHA General Election Manifesto asks (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation, particularly items relating to incentives/intellectual property rights; (ii) EU wide access to new medicines. (Legislation) | 10 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | Budget 2025 (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2024 | Irish Pharmaceutical Healthcare Association | Health | General discussion on issues regarding the reimbursement of medicines in Ireland and the European Commission proposed revision of the EU General Pharmaceutical Legislation. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2024 | Irish Pharmaceutical Healthcare Association | Health | (1) European Commission's proposed revision of EU Pharma Legislation and related matters, with particular attention to intellectual property rights provisions and competitiveness. (2) General discussion on issues… (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2024 | Irish Pharmaceutical Healthcare Association | Health | Raise awareness about the European Commission's revision of the EU Pharmaceutical Strategy and IPHA's key asks for the next European Parliament mandate. (Legislation) | 10 | On lobbying.ie |
| Jan–Apr 2024 | Irish Pharmaceutical Healthcare Association | Health | (1) Budget 2024 - the need for funding of new medicines. (2) Likely no provision for new developments funding to HSE for new medicines in Budget 2024. (3) Absence of funding for new medicines in Budget 2024. (4)… (Matters involving public funds) | 34 | On lobbying.ie |
| Sep–Dec 2023 | Irish Pharmaceutical Healthcare Association | Health | (1) Reimbursement process improvements under consideration in the Mazar's Working Group. (2) Delays within Medicines Reimbursement System. (3) Preparation for negotiation of a Framework Agreement in 2025. (4) Process… (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2023 | Irish Pharmaceutical Healthcare Association | Health | Review of EU Council and Parliament process for proposed amendments to pharmaceutical legislation. (Legislation) | 2 | On lobbying.ie |
| Sep–Dec 2023 | Irish Pharmaceutical Healthcare Association | Health | European Commission's proposed revision of EU Pharma Legislation and related matters, with particular attention to intellectual property rights provisions. (Legislation) | 4 | On lobbying.ie |
| May–Aug 2023 | Irish Pharmaceutical Healthcare Association | Health | Budget 2024 - Exchequer allocation to HSE for new medicines expenditure in 2024. (Matters involving public funds) | 3 | On lobbying.ie |
| May–Aug 2023 | Irish Pharmaceutical Healthcare Association | Health | Matters under consideration that the European EPSCO Council in June, including the proposed revision of the General Pharmaceutical Legislation. (Legislation) | 1 | On lobbying.ie |
| May–Aug 2023 | Irish Pharmaceutical Healthcare Association | Health | EU Pharmaceutical Strategy (Legislation) | 3 | On lobbying.ie |
| May–Aug 2023 | Irish Pharmaceutical Healthcare Association | Health | Proposed EU Commission Pharmaceutical Legislation (Legislation) | 1 | On lobbying.ie |
| May–Aug 2023 | Irish Pharmaceutical Healthcare Association | Health | Orphan Drugs and Health (Pricing and Supply of Medical Goods (Amendment) Bill 2021 (Legislation) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Irish Pharmaceutical Healthcare Association | Health | Agenda of the EU Competitiveness Council (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Irish Pharmaceutical Healthcare Association | Health | Reimbursement processes under the 2013 Health Act; - IPHA draft proposals (Matters involving public funds) | 1 | On lobbying.ie |
| Jan–Apr 2023 | Irish Pharmaceutical Healthcare Association | Health | Revision of pharmaceutical legislation by European Commission. (Legislation) | 9 | On lobbying.ie |
| Jan–Apr 2023 | Irish Pharmaceutical Healthcare Association | Health | Revision of pharmaceutical legislation by European Commission. (Legislation) | 10 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | Request meeting on improved transparency in the context of Sinn Féin's Healthcare (Transparent Payments) Bill 2022. (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | Congratulations on appointment. Seek support for fast access to new medicines and for innovation in the EU Pharmaceutical Strategy. (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | EU Policy matters and fast access for new and innovative medicines. (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | Forum, 'The Future of Medicines' (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | Security of energy supply in the context of the war on Ukraine and the biopharmaceutical industry's exposure to any potential outages. (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | Discuss the industry's position on innovation in the context of the EU Pharmaceutical Strategy (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | Medicines innovation - Arrange meeting with LIF (Danish biopharmaceutical association) to discuss policy matters in relation to medicines innovation (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | EU Pharmaceutical Strategy (Public policy or programme) | 13 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Report on investment in Europe and policy on Advanced Therapy Medicinal Products. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Potential meeting with management of investor company in Ireland. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Discussion on EU pharmaceutical strategy and other matters. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Entire medicines supply chain to be insulated from energy rationing. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Budget submission (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Support for innovation and IP in forthcoming EU Pharmaceutical Strategy (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Gas supplies and pharmaceutical production. (Legislation) | 4 | On lobbying.ie |
| Jan–Apr 2022 | Irish Pharmaceutical Healthcare Association | Health | (i) EU Pharmaceutical Policy; (ii) EFPIA WAIT Indicator Survey - Access to new medicines; (iii) Access to Orphan Medicines; (iv) EU Pharmaceutical Strategy (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2021 | Irish Pharmaceutical Healthcare Association | Health | Preparation for a meeting, management of negotiations, of a new framework agreement on the pricing and supply of medicines. (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2021 | Irish Pharmaceutical Healthcare Association | Health | IPHA Code of Practice for the Pharmaceutical Industry - including ToV disclosures. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2021 | Irish Pharmaceutical Healthcare Association | Health | Negotiations on a new framework agreement on supply and pricing of medicines. (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2021 | Irish Pharmaceutical Healthcare Association | Health | (i) WTO TRIPS Waiver of IP rights; (ii) Potential new supply agreement. (iii) Access to potential life sciences strategy. (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2021 | Irish Pharmaceutical Healthcare Association | Health | WTO TRIPS Waiver of IP rights (Public policy or programme) | 4 | On lobbying.ie |
| May–Aug 2021 | Irish Pharmaceutical Healthcare Association | Health | Access to new medicines & new supply agreement (Matters involving public funds) | 9 | On lobbying.ie |
| Jan–Apr 2021 | Irish Pharmaceutical Healthcare Association | Health | Report on Value of Expenditure on Medicines (Matters involving public funds) | 4 | On lobbying.ie |
| Jan–Apr 2021 | Irish Pharmaceutical Healthcare Association | Health | Urging the Government to oppose a waiver of IP rights at the WTO (Public policy or programme) | 2 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 182 | 100.0% |